Vaccine access amid political turmoil in Venezuela is the backdrop of institute director Richard Marlink’s comments, for a story published by Devex, about COVAX and a global response to the pandemic.
In an interview with The Daily Targum, institute director Richard Marlink explains the international collaboration to distribute COVID-19 vaccines more equitably worldwide.
Following the FDA’s emergency approval of Johnson & Johnson’s COVID-19 vaccine, ROI-NJ published a collection of health experts’ perspectives that includes institute director Richard Marlink’s comments about vaccine efficacy.
In an interview for WRSU Rutgers Radio, institute director Richard Marlink offers perspective on the importance of a global response to COVID-19, vaccine infrastructure in Africa, vaccine production and safety, and the World Health Organization.
Appearing on CNBC’s Power Lunch, core faculty member and Rutgers vice chancellor Reynold Panettieri discusses the Johnson & Johnson COVID-19 vaccine, infection rates and hospitalizations, and effective public health measures.
The global health consequences and moral implications of wealthy countries hoarding vaccines could be quite serious, said institute director Richard Marlink in a story published by The Daily Targum.
In a television interview broadcast by NJ Spotlight News, institute director Richard Marlink discusses the COVID-19 vaccine. Topics include how long immunity might last and roadblocks in rolling out a vaccination program.
Rutgers Global Health Institute director Richard Marlink is among the “experts, pundits, and social media users” interviewed for a national story about U.S. Congress members being among the first to receive coronavirus vaccines.
As researchers race to develop a COVID-19 vaccine, two Rutgers Global Health Institute core faculty members discuss how clinical trials work, the ethics of developing and distributing a vaccine, safety and efficacy in clinical trials, and what a successful vaccine may mean.
Health officials can’t rely on a one-size-fits-all message when it comes to communicating with the public about a forthcoming COVID-19 vaccine, says Professor William Hallman, an experimental psychologist who uses scientific research to explore human behavior.